Page 138 - 《中国药房》2024年2期

1239-1276. 15（10）：1171-1187.
[23] 李琳，黄桦，吴迪，等. 左乙拉西坦血药浓度影响因素探 [36] LI Y，WANG M L，GUO Y，et al. Population pharmacoki‐
讨及参考区间的初步建立[J]. 中国临床药理学杂志， netics and dosing regimen optimization of levetiracetam
2018，34（6）：643-645. in epilepsy during pregnancy[J]. Br J Clin Pharmacol，
LI L，HUANG H，WU D，et al. Reference range of leveti‐ 2023，89（3）：1152-1161.
racetam plasma concentration and its influencing factors [37] HIRSCH L J，ARIF H，BUCHSBAUM R，et al. Effect of
in our hospital[J]. Chin J Clin Pharmacol，2018，34（6）： age and comedication on levetiracetam pharmacokinetics
643-645. and tolerability[J]. Epilepsia，2007，48（7）：1351-1359.
[24] LANCELIN F，FRANCHON E，KRAOUL L，et al. Thera‐ [38] FRENCH J. Use of levetiracetam in special populations
peutic drug monitoring of levetiracetam by high- [J]. Epilepsia，2001，42（Suppl 4）：40-43.
performance liquid chromatography with photodiode ar‐ [39] YAMAMOTO J，TOUBLANC N，KUMAGAI Y，et al.
ray ultraviolet detection：preliminary observations on cor‐ Levetiracetam pharmacokinetics in Japanese subjects with
relation between plasma concentration and clinical re‐ renal impairment[J]. Clin Drug Investig，2014，34（11）：
sponse in patients with refractory epilepsy[J]. Ther Drug 819-828.
Monit，2007，29（5）：576-583. [40] MAHMOUD S H. Antiepileptic drug removal by continu‐
[25] STEPANOVA D，BERAN R G. Measurement of leveti‐ ous renal replacement therapy：a review of the literature
racetam drug levels to assist with seizure control and [J]. Clin Drug Investig，2017，37（1）：7-23.
monitoring of drug interactions with other anti-epileptic [41] MAY T W，RAMBECK B，JÜRGENS U. Serum concen‐
medications（AEMs）[J]. Seizure，2014，23（5）：371-376. trations of levetiracetam in epileptic patients：the in-
[26] IWASAKI T，TOKI T，NONODA Y，et al. The efficacy of fluence of dose and co-medication[J]. Ther Drug Monit，
levetiracetam for focal seizures and its blood levels in chil‐ 2003，25（6）：690-699.
dren[J]. Brain Dev，2015，37（8）：773-779. [42] MINK S，MUROI C，SEULE M，et al. Levetiracetam com‐
[27] SHEINBERG R，HEYMAN E，DAGAN Z，et al. Correla‐ pared to valproic acid：plasma concentration levels，ad‐
tion between efficacy of levetiracetam and serum levels verse effects and interactions in aneurysmal subarachnoid
among children with refractory epilepsy[J]. Pediatr Neu‐ hemorrhage[J]. Clin Neurol Neurosurg，2011，113（8）：
rol，2015，52（6）：624-628. 644-648.
[28] ALDAZ A，FERRIOLS R，AUMENTE D，et al. Pharma‐ [43] CRAWFORD P. Interactions between antiepileptic drugs
cokinetic monitoring of antiepileptic drugs[J]. Farm Hosp， and hormonal contraception[J]. CNS Drugs，2002，16（4）：
2011，35（6）：326-339. 263-272.
[29] ITALIANO D，PERUCCA E. Clinical pharmacokinetics [44] TOUBLANC N，DU X L，LIU Y，et al. Pharmacokinetics，
of new-generation antiepileptic drugs at the extremes of age： safety and bioequivalence of levetiracetam intravenous in‐
an update[J]. Clin Pharmacokinet，2013，52（8）：627-645. fusion and oral tablets in healthy Chinese subjects[J]. Clin
[30] JARVIE D，MAHMOUD S H. Therapeutic drug monito- Drug Investig，2015，35（8）：495-503.
ring of levetiracetam in select populations[J]. J Pharm [45] WANG M，WANG M M，ZHANG Q Y，et al. Pharmacoki‐
Pharm Sci，2018，21（1s）：149s-176s. netics and safety of levetiracetam extended-release tablets
[31] LÓPEZ-FRAILE I P，CID A O，JUSTE A O，et al. Leveti‐ and relative bioavailability compared with immediate-
racetam plasma level monitoring during pregnancy，deli- release tablets in healthy Chinese subjects[J]. Eur J Drug
very，and postpartum：clinical and outcome implications Metab Pharmacokinet，2018，43（4）：405-413.
[J]. Epilepsy Behav，2009，15（3）：372-375. [46] 廖淑芳. 癫痫伴发精神障碍患者服药依从性及其影响因
[32] TOMSON T，PALM R，KÄLLÉN K，et al. Pharmacokine- 素分析[J]. 中国当代医药，2022，29（23）：50-52，56.
tics of levetiracetam during pregnancy，delivery，in the LIAO S F. Analysis of medication compliance and its in‐
neonatal period，and lactation[J]. Epilepsia，2007，48（6）： fluencing factors of patients with epilepsy and mental dis-
1111-1116. order[J]. China Mod Med，2022，29（23）：50-52，56.
[33] WESTIN A A，REIMERS A，HELDE G，et al. Serum con‐ [47] 周艳，吴青，余春飞，等. 癫痫患儿用药依从性现状及影
centration/dose ratio of levetiracetam before，during and 响因素调查分析[J]. 儿科药学杂志，2022，28（7）：21-26.
after pregnancy[J]. Seizure，2008，17（2）：192-198. ZHOU Y，WU Q，YU C F，et al. Investigation and analy‐
[34] LONGO B，FORINASH A B，MURPHY J A. Levetirace‐ sis of medication adherence and influencing factors in
tam use in pregnancy[J]. Ann Pharmacother，2009，43 children with epilepsy[J]. J Pediatr Pharm，2022，28（7）：
（10）：1692-1695. 21-26.
[35] VOINESCU P E，PENNELL P B. Management of epi‐ （收稿日期：2023-07-20 修回日期：2023-12-20）
lepsy during pregnancy[J]. Expert Rev Neurother，2015， （编辑：孙 冰）

· 256 · China Pharmacy 2024 Vol. 35 No. 2 中国药房 2024年第35卷第2期